Last updated: March 3, 2026
What is Propoxyphene Compound-65?
Propoxyphene Compound-65 is a formulation based on propoxyphene, an opioid analgesic used to treat mild to moderate pain. The compound combines propoxyphene with other agents to improve efficacy or reduce side effects. Historically, propoxyphene was marketed under brand names including Darvon and Darvocet.
Market Status and Regulatory Landscape
Historical Market Presence
Propoxyphene was broadly prescribed from the 1950s through early 2010s. In 2010, the U.S. Food and Drug Administration (FDA) requested the withdrawal of propoxyphene products due to safety concerns, primarily cardiotoxicity risks. This caused a significant decline in sales and approval withdrawal in key markets.
Regulatory Actions
- FDA (2010): Issued a final rule to remove propoxyphene from the market after reviews found increased risk of serious or life-threatening cardiac arrhythmias.
- European Medicines Agency (EMA): Similar restrictions imposed globally.
- Legal Trends: Multiple class-action lawsuits alleging misuse and harm contributed to market exit.
Current Status
As of 2023, propoxyphene formulations are largely unavailable commercially in major markets. However, proprietary formulations like Propoxyphene Compound-65 may be under development or in preclinical/clinical phases aiming to address longstanding safety issues.
Investment Fundamentals
Patent and Intellectual Property Landscape
-
Patent Status: Propoxyphene's original patents expired decades ago. Any current Compound-65 formulations depend on new patent filings, formulation patents, or combination patent strategies.
-
Patent life: If filed recently, patent protection may extend 20 years from filing date, typically until 2035-2040, depending on jurisdiction.
Market Appetite and Competitive Landscape
- Demand: No current over-the-counter (OTC) or prescription demand exists in major markets due to historical safety concerns.
- Niche applications: Potential exists in pain management research if safety risks can be mitigated.
- Competitors: Alternatives such as acetaminophen, NSAIDs, or newer opioids (e.g., tapentadol) dominate the mild-moderate pain market.
Clinical and Safety Profile
- History of Toxicity: Increased cardiac risks led regulators to withdraw approval for propoxyphene-based drugs.
- Current research: Formulation modifications aim to improve safety profiles, including reduced cardiotoxicity.
R&D and Regulatory Risk
- High R&D costs: Substantial investments needed to demonstrate safety and efficacy in new formulations.
- Regulatory hurdles: Re-establishing market approval involves extensive clinical trials, which face skepticism due to past safety records.
- Market re-entry risk: Very high without compelling safety data and substantial regulatory clearance.
Financial Analysis
| Parameter |
Detail |
| R&D Cost |
Estimated $200M-$350M for clinical development and approval processes, depending on scope. |
| Time to Market |
3-5 years, assuming accelerated pathways or orphan drug designation. |
| Revenue Potential |
Limited; revisited safety profiles could create niche markets for pain management with low abuse risk. Estimated peak annual sales: <$50M unless broad re-approval occurs. |
| Licensing/Partnerships |
Opportunities to license or co-develop with companies focused on safer opioid formulations. |
Strategic Considerations
- Regulatory risk remains substantial; any new formulation must demonstrate a markedly improved safety profile.
- Market risk is high due to decline in demand for opioids and increased focus on non-opioid pain treatments.
- Intellectual property viability depends on new patent filings and formulation innovations.
- Distressed asset potential exists if a company owns a proprietary formulation with demonstrated safety and efficacy.
Key Takeaways
- Propoxyphene Compound-65 faces significant hurdles in re-entering the market due to historical safety issues.
- High R&D costs and regulatory uncertainty limit immediate commercial viability.
- Potential exists in niche pain management segments if safety can be substantially improved.
- Current market trends favor non-opioid alternatives over reformed opioids.
- Investment should focus on proprietary formulations demonstrating safety advantages and regulatory acceptance.
FAQs
1. Is Propoxyphene Compound-65 likely to regain regulatory approval?
It is unlikely unless it demonstrates a significant safety profile improvement, especially regarding cardiotoxicity, supported by robust clinical data.
2. What are the main risks associated with investing in such formulations?
Key risks include regulatory rejection, high R&D costs, market rejection due to safety concerns, and competition from established non-opioid analgesics.
3. Are there any current clinical trials for Propoxyphene-based formulations?
As of 2023, no publicly available trials focus on Propoxyphene Compound-65 specifically; research efforts are limited and experimental.
4. What is the potential market size for reformulated Propoxyphene derivatives?
Potential niche markets exist in pain management, estimated under $50 million annually, contingent on safety validation.
5. Which regulatory pathways could facilitate faster approval?
Orphan drug designation or breakthrough therapy designation could shorten development timelines if safety evidence is compelling.
References
[1] U.S. Food and Drug Administration. (2010). FDA requests removal of propoxyphene from the market.
[2] European Medicines Agency. (2010). Safety review of propoxyphene.
[3] Smith, J. L., & Johnson, R. M. (2021). Reformulation strategies for opioid analgesics. Journal of Drug Development, 12(4), 205-218.
[4] GlobalData. (2022). Opioid pain management market outlook.
[5] patent data sources, 2023.
